CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This activity is intended for medical oncologists, hematologist-oncologists and other healthcare providers involved in the treatment of breast cancer (BC).
  
  OVERVIEW OF ACTIVITY
  BC continues to be one of the most rapidly evolving fields in medical oncology. Results from numerous ongoing trials lead to the continual emergence of new therapeutic agents, treatment strategies and diagnostic and prognostic tools. In order to offer optimal patient care, including the option of clinical trial participation, the practicing cancer clinician must be well informed of these advances. Featuring information on the latest research developments along with expert perspectives, this CME activity is designed to assist medical oncologists, hematologist-oncologists and hematology-oncology fellows with the formulation of up-to-date clinical management strategies.
  
  LEARNING OBJECTIVES

  • Implement a long-term clinical plan for the management of metastatic HER2-positive BC, incorporating existing, recently approved and emerging targeted treatments.
  • Consider published data to guide the use of biomarkers and genomic assays to assess risk and individualize therapy for patients with hormone receptor-positive BC in the neoadjuvant, adjuvant and extended-adjuvant settings.
  • Develop an evidence-based algorithm for the treatment of advanced, hormone receptor-positive pre- and postmenopausal BC, including the use of endocrine, biologic and chemotherapeutic agents.
  • Consider published research and patient preferences in the selection and sequencing of available and investigational therapeutic agents for metastatic triple-negative BC.
  • Counsel appropriately selected patients with BC about participation in ongoing clinical trials.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  CME credit is no longer available for this issue
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  CME credit is no longer available for this issue
  
  HOW TO USE THESE CME ACTIVITIES
  Audio Program: This CME activity consists of an audio component.
  CME credit is no longer available for this issue
  
  Video Program: This CME activity consists of a video component.
  CME credit is no longer available for this issue
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:
  
  Eric P Winer, MD
  Senior Vice President for Medical Affairs
  Chief, Division of Breast Oncology
  Thompson Chair in Breast Cancer Research
  Dana-Farber Cancer Institute
  Professor of Medicine, Harvard Medical School
  Boston, Massachusetts
  
  Advisory Committee: Genentech, Leap Therapeutics Inc, Lilly, Tesaro Inc.
  
  Daniel F Hayes, MD
  Stuart B Padnos Professor of Breast Cancer Research
  University of Michigan Rogel Cancer Center
  Professor, Internal Medicine
  Michigan Medicine
  Ann Arbor, Michigan
  
  Consulting Agreements: Artiman Ventures (Cellworks), Cepheid, CVS Caremark Breast Cancer Expert Panel, Freenome Inc; Contracted Research: AstraZeneca Pharmaceuticals LP, Johnson & Johnson Pharmaceuticals, Lilly, Menarini Silicon Biosystems, Merrimack Pharmaceuticals Inc, Pfizer Inc, Puma Biotechnology Inc, Veridex LLC; Royalties from Licenses Technology: Janssen Biotech Inc; Stock: Inbiomotion, Oncimmune Ltd.
  
  Ingrid A Mayer, MD, MSCI
  Ingram Professor of Cancer Research
  Professor of Medicine
  Leader, VICC Breast Cancer Research Program
  Co-Principal Investigator, VICC Breast Cancer SPORE
  Division of Hematology-Oncology
  Vanderbilt-Ingram Cancer Center
  Nashville, Tennessee
  
  Advisory Committee: AstraZeneca Pharmaceuticals LP, Lilly, Novartis; Contracted Research: Genentech, Pfizer Inc.
  
  EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech, Genomic Health Inc, Gilead Sciences Inc, Guardant Health, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite Pharma Inc, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology, Medivation Inc, a Pfizer Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seattle Genetics, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro Inc, Teva Oncology and Tokai Pharmaceuticals Inc.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Eisai Inc, Genomic Health Inc, Lilly, Merck, Novartis, Pfizer Inc, Puma Biotechnology Inc and Seattle Genetics.
  
  Hardware/Software Requirements:
  A high-speed Internet connection
  A monitor set to 1280 x 1024 pixels or more
  Internet Explorer 11 or later, Firefox 56 or later, Chrome 61 or later, Safari 11 or later, Opera 48 or later
  Adobe Flash Player 27 plug-in or later
  Adobe Acrobat Reader
  (Optional) Sound card and speakers for audio
  
  Release date: January 2019
  Expiration date: January 2020